Quantum BioPharma Challenges Major Financial Institutions Over Alleged Market Manipulation

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has publicly opposed a joint motion to dismiss filed by CIBC World Markets and RBC Dominion Securities in a U.S. District Court, marking a significant step in a legal battle over alleged market manipulation. The lawsuit, which seeks over $700 million in damages, accuses these institutions of engaging in 'spoofing' activities between January 1, 2020, and August 15, 2024, actions that Quantum claims have violated federal securities laws and artificially depressed its stock price.

The legal action, pursued on a contingency basis by Christian Attar and Freedman Normand Friedland LLP, highlights hundreds of spoofing instances that allegedly impacted Quantum's stock, which once traded above $460 per share. This case not only seeks reparations for the purported harm caused to Quantum and its investors but also questions the effectiveness of current securities laws and regulatory mechanisms in protecting the market's integrity. For more information on the case, visit https://ibn.fm/aVf7r.

Amidst its legal challenges, Quantum BioPharma remains committed to its core mission in the biopharmaceutical sector, focusing on developing innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. This dual focus on advancing medical science and ensuring corporate accountability underscores the company's dedication to its stakeholders and the broader societal good.